Advanced search
1 file | 472.22 KB Add to list

Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy

(2009) AIDS. 23(13). p.1689-1699
Author
Organization
Keywords
CONTROLLED TRIAL, HIV-1-INFECTED PATIENTS, PROSPECTIVE COHORT, DOUBLE-BLIND, HYPERSENSITIVITY, PROTEASE INHIBITORS, CD4 CELL COUNTS, HIV-INFECTED PATIENTS, toxicity, viral load, nevirapine, HIV, CD4 cell count, RASH, HEPATOTOXICITY

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 472.22 KB

Citation

Please use this url to cite or link to this publication:

MLA
Kesselring, Anouk M, Ferndinand W Wit, Caroline A Sabin, et al. “Risk Factors for Treatment-limiting Toxicities in Patients Starting Nevirapine-containing Antiretroviral Therapy.” AIDS 23.13 (2009): 1689–1699. Print.
APA
Kesselring, A. M., Wit, F. W., Sabin, C. A., Lundgren, J. D., Gill, M. J., Gatell, J. M., Rauch, A., et al. (2009). Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. AIDS, 23(13), 1689–1699.
Chicago author-date
Kesselring, Anouk M, Ferndinand W Wit, Caroline A Sabin, Jens D Lundgren, M John Gill, Jose M Gatell, Andri Rauch, et al. 2009. “Risk Factors for Treatment-limiting Toxicities in Patients Starting Nevirapine-containing Antiretroviral Therapy.” Aids 23 (13): 1689–1699.
Chicago author-date (all authors)
Kesselring, Anouk M, Ferndinand W Wit, Caroline A Sabin, Jens D Lundgren, M John Gill, Jose M Gatell, Andri Rauch, Julio S Montaner, Frank De Wolf, Peter Reiss, Amanda Mocroft, the Nevirapine Toxicity Multicohort, and Linos Vandekerckhove. 2009. “Risk Factors for Treatment-limiting Toxicities in Patients Starting Nevirapine-containing Antiretroviral Therapy.” Aids 23 (13): 1689–1699.
Vancouver
1.
Kesselring AM, Wit FW, Sabin CA, Lundgren JD, Gill MJ, Gatell JM, et al. Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. AIDS. 2009;23(13):1689–99.
IEEE
[1]
A. M. Kesselring et al., “Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy,” AIDS, vol. 23, no. 13, pp. 1689–1699, 2009.
@article{3227485,
  author       = {Kesselring, Anouk M and Wit, Ferndinand W and Sabin, Caroline A and Lundgren, Jens D and Gill, M John and Gatell, Jose M and Rauch, Andri and Montaner, Julio S and De Wolf, Frank and Reiss, Peter and Mocroft, Amanda and Nevirapine Toxicity Multicohort, the and Vandekerckhove, Linos},
  issn         = {0269-9370},
  journal      = {AIDS},
  keywords     = {CONTROLLED TRIAL,HIV-1-INFECTED PATIENTS,PROSPECTIVE COHORT,DOUBLE-BLIND,HYPERSENSITIVITY,PROTEASE INHIBITORS,CD4 CELL COUNTS,HIV-INFECTED PATIENTS,toxicity,viral load,nevirapine,HIV,CD4 cell count,RASH,HEPATOTOXICITY},
  language     = {eng},
  number       = {13},
  pages        = {1689--1699},
  title        = {Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy},
  url          = {http://dx.doi.org/10.1097/QAD.0b013e32832d3b54},
  volume       = {23},
  year         = {2009},
}

Altmetric
View in Altmetric
Web of Science
Times cited: